{
    "clinical_study": {
        "@rank": "78784", 
        "arm_group": {
            "arm_group_label": "PCI-32765", 
            "arm_group_type": "Experimental", 
            "description": "Alternative anticancer treatment is selected at the investigator's discretion. For a patient randomized to chlorambucil in the parent study PCYC-1115-CA, PCI-32765 is an option for second-line therapy, provided the patient meets the criteria for second-line PCI-32765 therapy. For a patient randomized to PCI-32765 in the parent study PCYC-1115-CA, the patient will continue on PCI-32765 at the parent study."
        }, 
        "brief_summary": {
            "textblock": "An Open-label Extension Study in Patients 65 Years or Older with Chronic Lymphocytic\n      Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) Who Participated in Study PCYC-1115-CA\n      (PCI-32765 versus Chlorambucil)"
        }, 
        "brief_title": "An Open-label Extension Study in Patients 65 Years or Older With Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) Who Participated in Study PCYC-1115-CA (PCI-32765 Versus Chlorambucil)", 
        "completion_date": {
            "#text": "February 2018", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Chronic Lymphocytic Leukemia", 
            "Small Lymphocytic Lymphoma"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Leukemia", 
                "Leukemia, Lymphocytic, Chronic, B-Cell", 
                "Leukemia, Lymphoid", 
                "Lymphoma"
            ]
        }, 
        "detailed_description": {
            "textblock": "Study PCYC-1116-CA is an open-label, multicenter extension of Study PCYC 1115-CA\n      (RESONATE\u2122-2, the parent study), and it will run concurrently with the parent study.  A\n      patient will be transferred to PCYC-1116-CA after Independent Review Committee (IRC)\n      confirmation of disease progression (PD) in the parent study or at closure of the parent\n      study by the sponsor, whichever comes first.\n\n      After PD, selection of second-line therapy, when clinically indicated, is at the discretion\n      of the investigator and can include second-line PCI-32765 (for patients randomized to\n      chlorambucil in the parent study who also meet the criteria for second-line PCI-32765\n      therapy), second-line chlorambucil (for patients randomized to PCI-32765 in the parent\n      study), or other therapies.\n\n      Assessments in the extension study vary depending on the treatment to which the patient was\n      randomized in the parent study, the disease-progression status at transfer to the extension\n      study, and the planned treatment in the extension study."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Randomized in the parent study, PCYC-1115-CA\n\n          2. Informed consent for Study PCYC-1116-CA\n\n          3. IRC-confirmed PD in the parent study PCYC-1115-CA or closure of the parent study\n\n        Exclusion Criteria:\n\n          -  N/A"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "65 Years"
        }, 
        "enrollment": {
            "#text": "272", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "November 2, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01724346", 
            "org_study_id": "PCYC-1116-CA", 
            "secondary_id": "2012-003968-44"
        }, 
        "intervention": {
            "arm_group_label": "PCI-32765", 
            "description": "PCI-32765 will be supplied as hard gelatin 140-mg capsules for oral (PO) administration.PCI-32765 420 mg (3 x 140-mg capsules) is administered orally once daily. The first dose will be delivered in the clinic on Day 1, after which subsequent dosing is typically on an outpatient basis. PCI-32765 will be dispensed to patients in bottles at every other visit.", 
            "intervention_name": "PCI-32765", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": "Chlorambucil"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": "CLL, SLL", 
        "lastchanged_date": "February 13, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Houston", 
                    "country": "United States", 
                    "state": "Texas", 
                    "zip": "77030"
                }, 
                "name": "MD Anderson Cancer Center"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "An Open-label Extension Study in Patients 65 Years or Older With Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) Who Participated in Study PCYC-1115-CA (PCI-32765 Versus Chlorambucil)", 
        "overall_official": {
            "affiliation": "Pharmacyclics", 
            "last_name": "Lori Styles, MD", 
            "role": "Study Director"
        }, 
        "overall_status": "Enrolling by invitation", 
        "oversight_info": {
            "authority": [
                "United States: Food and Drug Administration", 
                "Australia: Department of Health and Ageing Therapeutic Goods Administration", 
                "Belgium: Federal Agency for Medicinal Products and Health Products", 
                "Canada: Health Canada", 
                "China: Food and Drug Administration", 
                "Czech Republic: State Institute for Drug Control", 
                "Germany: Federal Institute for Drugs and Medical Devices", 
                "Ireland: Irish Medicines Board", 
                "Israel: Israeli Health Ministry Pharmaceutical Administration", 
                "Italy: The Italian Medicines Agency", 
                "New Zealand: Food Safety Authority", 
                "Poland: Office for Registration of Medicinal Products, Medical Devices and Biocidal Products", 
                "Spain: Agencia Espa\u00f1ola de Medicamentos y Productos Sanitarios", 
                "Turkey: Ministry of Health", 
                "United Kingdom: Medicines and Healthcare Products Regulatory Agency", 
                "Ukraine: State Pharmacological Center - Ministry of Health"
            ]
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "June 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Progression Free Survial on first-line therapy for those patients who did not experience PD in the parent study\nProgression Free Survial on second-line anticancer therapy\nOverall survival\nFor patients who discontinued first-line therapy, time from the end of firstline therapy to the beginning of second-line therapy\nOverall Response Rate, DOR, Progression Free Survial, and Overall survial on subsequent therapy for patients progressing in the parent study\nSafety as measured by Grade 3, 4, 5 AEs, AEs leading to discontinuation, and serious adverse events (SAEs)\nDisease outcome following cessation of PCI-32765 treatment after attainment of minimal residual disease (MRD)-negative remission in those patients receiving PCI-32765 as second-line therapy", 
            "measure": "PFS", 
            "safety_issue": "No", 
            "time_frame": "5 years"
        }, 
        "removed_countries": {
            "country": [
                "Australia", 
                "Belgium", 
                "Canada", 
                "China", 
                "Czech Republic", 
                "Ireland", 
                "Israel", 
                "Italy", 
                "New Zealand", 
                "Poland", 
                "Russian Federation", 
                "Spain", 
                "Turkey", 
                "Ukraine", 
                "United Kingdom"
            ]
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01724346"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Pharmacyclics", 
        "sponsors": {
            "collaborator": {
                "agency": "Janssen Research & Development, LLC", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "Pharmacyclics", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "January 2013", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "December 2013"
    }
}